Cullinan Therapeutics (CGEM) Income from Continuing Operations (2021 - 2023)
Historic Income from Continuing Operations for Cullinan Therapeutics (CGEM) over the last 3 years, with Q4 2023 value amounting to -$25.6 million.
- Cullinan Therapeutics' Income from Continuing Operations rose 555.66% to -$25.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$155.1 million, marking a year-over-year decrease of 24197.15%. This contributed to the annual value of -$167.6 million for FY2024, which is 804.25% down from last year.
- Latest data reveals that Cullinan Therapeutics reported Income from Continuing Operations of -$25.6 million as of Q4 2023, which was up 555.66% from -$39.2 million recorded in Q3 2023.
- Over the past 5 years, Cullinan Therapeutics' Income from Continuing Operations peaked at $174.1 million during Q2 2022, and registered a low of -$58.1 million during Q1 2023.
- Over the past 3 years, Cullinan Therapeutics' median Income from Continuing Operations value was -$25.2 million (recorded in 2022), while the average stood at -$9.4 million.
- Over the last 5 years, Cullinan Therapeutics' Income from Continuing Operations had its largest YoY gain of 115885.39% in 2022, and its largest YoY loss of 100627.2% in 2022.
- Cullinan Therapeutics' Income from Continuing Operations (Quarter) stood at -$34.2 million in 2021, then increased by 20.87% to -$27.1 million in 2022, then grew by 5.56% to -$25.6 million in 2023.
- Its last three reported values are -$25.6 million in Q4 2023, -$39.2 million for Q3 2023, and -$32.2 million during Q2 2023.